US 2025/0051435 A1Published application

Anti-il-5 antibodies and uses thereof

AssigneeInvetx, Inc.

InventorsWilliam BRONDYK, Leila SEVIGNY

Life of this patent

Estimating the term…

Abstract

The invention provides novel anti-IL-5 proteins, antibodies and IL-5 binding fragments thereof, which inhibit association of IL-5 with IL-5 receptor and are suitable for administration to a human or feline subject. The invention provides novel compositions and methods of treating, alleviating the symptoms of, or preventing, lung diseases, cardiovascular diseases, cancers, metabolic diseases, neurological diseases, and infectious diseases, comprising administering an effective amount of an anti-IL-5 protein, antibody, or fragment thereof. The methods and compositions are used to treat or prevent IL-5-related disorders.

Claims25

Dependent claims

An antigen binding protein that specifically binds to interleukin-5 (IL-5), which comprises:

(a) a heavy chain complementarity determining region 1 (HCDR1) comprising X1X2X3X4X5X6X7X8, wherein X1 comprises A, G, I, L, M, W, F, P, or V, X2 comprises A, G, I, L, M, W, F, P, or V, X3 comprises C, S, T, Y, N, or Q, X4 comprises A, G, I, L, M, W, F, P, or V, X5 comprises A, G, I, L, M, W, F, P, or V, X6 comprises H, K, or R, X7 comprises C, S, T, Y, N, or Q, and X8 comprises C, S, T, Y, N, or Q;
(b) a heavy chain complementarity determining region 2 (HCDR2) comprising X1X2X3X4X5X6X7X8, wherein X1 comprises A, G, I, L, M, W, F, P, or V, X2 comprises A, G, I, L, M, W, F, P, or V, X3 comprises C, S, T, Y, N, or Q, X4 comprises A, G, I, L, M, W, F, P, or V, X5 comprises A, G, I, L, M, W, F, P, or V, X6 comprises H, K, or R, X7 comprises C, S, T, Y, N, or Q, and X8 comprises a C, S, T, Y, N, or Q;
(c) a heavy chain complementarity determining region 3 (HCDR3) comprising X1X2X3X4X5X6X7X8X9X10X11X12, wherein X1 comprises C, S, T, Y, N, or Q, X2 comprises H, K, or R, X3 comprises an E or D, X4 comprises C, S, T, Y, N, or Q, X5 comprises E or D, X6 comprises A, G, I, L, M, W, F, P, or V, X7 comprises C, S, T, Y, N, or Q, X8 comprises D, E, or G, X9 comprises A, G, I, L, M, W, F, P, or V, X10 comprises A, G, I, L, M, W, F, P, or V, X11 comprises D, E, or L, and X12 comprises C, L, S, T, V, Y, N, or Q;
(d) a light chain complementarity determining region 1 (LCDR1) comprising X1X2X3X4X5X6, wherein X1 comprises C, S, T, Y, N, or Q, X2 comprises C, S, T, Y, N, or Q, X3 comprises A, G, I, L, M, W, F, P, or V, X4 comprises C, S, T, Y, N, or Q, X5 comprises E or D, and X6 comprises C, S, T, Y, N, or Q;
(e) a light chain complementarity determining region 2 (LCDR2) comprising X1X2X3X4X5X6X7X8X9X10, wherein X1 comprises L or R, X2 comprises A, G, I, L, M, W, F, P, or V, X2 comprises A, G, I, L, M, W, F, P, or V, X4 comprises C, S, T, Y, N, or Q, X5 comprises C, S, T, Y, N, or Q, X6 comprises D, E, A, G, I, L, M, W, F, P, or V, X7 comprises C, S, T, Y, N, or Q, X8 comprises C, S, T, Y, N, Q, A, G, I, L, M, W, F, P, or V, X9 comprises D, E, C, S, T, Y, N, or Q, X10 comprises A, G, I, L, M, W, F, P, Y or V;
and
(f) a light chain complementarity determining region 3 (LCDR3) comprising X1X2X3X4X5X6X7X8X9, wherein X1 comprises C, S, T, Y, N, or Q, X2 comprises C, S, T, Y, N, or Q, X3 comprises A, G, I, L, M, W, F, P, or V, X4 comprises A, H, I, K, L, M, P, R, S, V, or Y, X5 comprises C, F, I, L, R, S, T, Y, N, or Q, X6 comprises A, G, I, L, M, W, F, P, or V, X7 comprises A, G, I, L, M, W, F, P, or V, X8 comprises C, S, T, F, Y, N, or Q, and X9 comprises C, S, T, Y, N, or Q.

4 more elements

Dependencies are inferred from the claim text.

Facts

Application: 18/799,544Filed 9 Aug 2024
Priority: 11 Aug 2023
Published: 13 Feb 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification8 codes

C07K 16/244
Against cytokines, lymphokines or interferons: interleukins [IL]
A61K 2039/552
Characterised by the host/recipient, e.g. newborn with maternal antibodies: veterinary vaccine
C07K 2317/24
Characterized by taxonomic origin: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/565
Variable region, i.e. VH and/or VL: complementarity determining region [CDR]

Family

Application63/532,157Us provisional application · filed 11 Aug 2023
US 2025/0051435 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

An antigen binding protein that specifically binds to interleukin-5 (IL-5), which comprises:

(a) a heavy chain complementarity determining region 1 (HCDR1) comprising X1X2X3X4X5X6X7X8, wherein X1 comprises A, G, I, L, M, W, F, P, or V, X2 comprises A, G, I, L, M, W, F, P, or V, X3 comprises C, S, T, Y, N, or Q, X4 comprises A, G, I, L, M, W, F, P, or V, X5 comprises A, G, I, L, M, W, F, P, or V, X6 comprises H, K, or R, X7 comprises C, S, T, Y, N, or Q, and X8 comprises C, S, T, Y, N, or Q;
(b) a heavy chain complementarity determining region 2 (HCDR2) comprising X1X2X3X4X5X6X7X8, wherein X1 comprises A, G, I, L, M, W, F, P, or V, X2 comprises A, G, I, L, M, W, F, P, or V, X3 comprises C, S, T, Y, N, or Q, X4 comprises A, G, I, L, M, W, F, P, or V, X5 comprises A, G, I, L, M, W, F, P, or V, X6 comprises H, K, or R, X7 comprises C, S, T, Y, N, or Q, and X8 comprises a C, S, T, Y, N, or Q;
(c) a heavy chain complementarity determining region 3 (HCDR3) comprising X1X2X3X4X5X6X7X8X9X10X11X12, wherein X1 comprises C, S, T, Y, N, or Q, X2 comprises H, K, or R, X3 comprises an E or D, X4 comprises C, S, T, Y, N, or Q, X5 comprises E or D, X6 comprises A, G, I, L, M, W, F, P, or V, X7 comprises C, S, T, Y, N, or Q, X8 comprises D, E, or G, X9 comprises A, G, I, L, M, W, F, P, or V, X10 comprises A, G, I, L, M, W, F, P, or V, X11 comprises D, E, or L, and X12 comprises C, L, S, T, V, Y, N, or Q;
(d) a light chain complementarity determining region 1 (LCDR1) comprising X1X2X3X4X5X6, wherein X1 comprises C, S, T, Y, N, or Q, X2 comprises C, S, T, Y, N, or Q, X3 comprises A, G, I, L, M, W, F, P, or V, X4 comprises C, S, T, Y, N, or Q, X5 comprises E or D, and X6 comprises C, S, T, Y, N, or Q;
(e) a light chain complementarity determining region 2 (LCDR2) comprising X1X2X3X4X5X6X7X8X9X10, wherein X1 comprises L or R, X2 comprises A, G, I, L, M, W, F, P, or V, X2 comprises A, G, I, L, M, W, F, P, or V, X4 comprises C, S, T, Y, N, or Q, X5 comprises C, S, T, Y, N, or Q, X6 comprises D, E, A, G, I, L, M, W, F, P, or V, X7 comprises C, S, T, Y, N, or Q, X8 comprises C, S, T, Y, N, Q, A, G, I, L, M, W, F, P, or V, X9 comprises D, E, C, S, T, Y, N, or Q, X10 comprises A, G, I, L, M, W, F, P, Y or V;
and
(f) a light chain complementarity determining region 3 (LCDR3) comprising X1X2X3X4X5X6X7X8X9, wherein X1 comprises C, S, T, Y, N, or Q, X2 comprises C, S, T, Y, N, or Q, X3 comprises A, G, I, L, M, W, F, P, or V, X4 comprises A, H, I, K, L, M, P, R, S, V, or Y, X5 comprises C, F, I, L, R, S, T, Y, N, or Q, X6 comprises A, G, I, L, M, W, F, P, or V, X7 comprises A, G, I, L, M, W, F, P, or V, X8 comprises C, S, T, F, Y, N, or Q, and X9 comprises C, S, T, Y, N, or Q.

4 more elements

Facts

Application

18/799,544Filed 9 Aug 2024

Priority

11 Aug 2023

Published

13 Feb 2025

Term ends

Not estimatedThe source records don’t support an estimate.

Classification8 codes

C07K 16/244
Against cytokines, lymphokines or interferons: interleukins [IL]
A61K 2039/552
Characterised by the host/recipient, e.g. newborn with maternal antibodies: veterinary vaccine
C07K 2317/24
Characterized by taxonomic origin: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/565
Variable region, i.e. VH and/or VL: complementarity determining region [CDR]